SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

SIGA Technologies, Inc.NASDAQ: SIGA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $2.7T rose 78107034.3% year over year, ahead of the +25130615.4% change in trailing-twelve-month research & development. Over 3 fiscal years it compounded at -33.8% a year.

Context

  • Research & development amounted to 6.9% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +78107034.3% holds above the trailing-twelve-month pace of +25130615.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.7T+32244490.8% QoQ
Last fiscal yearDec 2025
$6.53M-47.0% YoY
LTMMar 2026
$2.7T+25130615.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78107034.3%——
1 year-47.0%——
3-year CAGR-33.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.53M USD
Year-over-year change
-47.0%
4-year CAGR
-10.0%

Research & Development vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25130615.4% is the highest of 10, against a peer median of -3.9%.
  • Research & development amounts to 2884018.5% of revenue for SIGA, versus a peer median of 11.4%.
SIGA Competitors
Research & Development for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$2.7T USD+25130615.4%-33.8%2884018.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M USD+40.8%+24.2%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$69.1M USD-13.8%-14.9%194.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M USD-30.6%-34.1%7.3%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$49.06M USD+2.0%+3.9%9.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$44.28M USD-2.4%-26.2%10.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M USD+41.7%-17.9%12.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M USD-18.6%-0.6%31.9%
DRIODarioHealth Corp.LTM Mar 2026$12.07M USD-44.2%-11.1%56.9%
SNDLSNDL Inc.LTM Mar 2026CA$393K CAD-3.9%-41.5%0.0%
Peer median (excluding SIGA) —-3.9%-14.9%11.4%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.